One Casualty As Takeda Refocuses Vaccine Priorities
This article was originally published in PharmAsia News
Takeda has decided to end the development of a combination vaccine for polio and other disorders as part of a broader reevaluation of its vaccines pipeline to focus on outstanding global needs.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.